K Pharma,Inc.

As of June 30, 2026, K Pharma,Inc. carries a market capitalization of 7.97B, placing it among publicly traded companies globally. Its enterprise value stands at 7.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

K Pharma,Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, K Pharma,Inc. has 11.62M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, K Pharma,Inc. maintains a current ratio of 18.65, meaning it holds 18.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, K Pharma,Inc.'s stock has gained approximately 2.42% over the past 52 weeks. The 50-day moving average sits at 773.30, while the 200-day moving average is 740.75.

As of June 30, 2026, K Pharma,Inc. holds 2.36B in cash and equivalents against 1.64B in total debt, resulting in a net debt position of -726.72M. Total book value stands at 773.65M, with working capital of 2.37B providing operational flexibility.